Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Pfizer

Status and phase: Completed; Phase 3

Conditions: Metastatic Breast Cancer

Treatments: Drug: Megestrol acetate; Drug: exemestane (Aromasin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01237327

971-ONC-0028-094

A5991027

Details and patient eligibility

About

Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.

Enrollment: 84 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previous participation in study 971-ONC-0028-080.

Exclusion criteria

• Subjects who had not previously participated in study 971-ONC-0028-080.

Trial design

84 participants in 2 patient groups

1

Active Comparator group

Treatment:

Drug: Megestrol acetate

2

Experimental group

Treatment:

Drug: exemestane (Aromasin)